The FDA has granted Fast Track and QIPD designations to CMTX-101 for the treatment of CF in patients affected by chronic bacterial pulmonary infections.

The BeLPT has high specificity for identifying chronic beryllium disease but poor sensitivity in distinguishing it from sarcoidosis.

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.